Cargando…

Lymphocyte recovery after fingolimod discontinuation in patients with MS

OBJECTIVE: To investigate the dynamics of immune cells recovery after treatment discontinuation of fingolimod in real-life clinical practice, we analyzed the course of lymphocyte reconstitution and its potential influencing factors in patients with multiple sclerosis (MS). METHODS: We analyzed leuko...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagy, Sara, Kuhle, Jens, Derfuss, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641093/ https://www.ncbi.nlm.nih.gov/pubmed/32801166 http://dx.doi.org/10.1212/NXI.0000000000000874

Ejemplares similares

Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis
por: Cerdá-Fuertes, Nuria, et al.
Publicado: (2023)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
por: Bianco, Assunta, et al.
Publicado: (2021)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
por: Diebold, Martin, et al.
Publicado: (2019)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
por: Vermersch, Patrick, et al.
Publicado: (2017)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod
por: Piñar Morales, Raquel, et al.
Publicado: (2022)

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS
por: Fox, Edward J., et al.
Publicado: (2019)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption
por: De Masi, Roberto, et al.
Publicado: (2015)

Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
por: Chan, Andrew, et al.
Publicado: (2020)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
por: Serpero, Laura D., et al.
Publicado: (2013)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Fingolimod in children with Rett syndrome: the FINGORETT study
por: Naegelin, Yvonne, et al.
Publicado: (2021)

Narrative review based on fingolimod therapy in pediatric MS
por: Piri Cinar, Bilge, et al.
Publicado: (2023)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
Publicado: (2018)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report
por: Akiyama, Hisanao, et al.
Publicado: (2016)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
por: Hersh, Carrie M, et al.
Publicado: (2020)

Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study
por: Nishiyama, Shuhei, et al.
Publicado: (2017)

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
por: Hersh, Carrie M, et al.
Publicado: (2017)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
por: Hasan Ali, Omar, et al.
Publicado: (2020)

Beneficial effects of fingolimod in MS patients with high serum Sema4A levels
por: Koda, Toru, et al.
Publicado: (2018)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Mass Cytometry of CSF Identifies an MS-Associated B-cell Population
por: Johansson, David, et al.
Publicado: (2021)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tgk5f1hiuc979opniemgjck19u